2021
The impact of a universal human papilloma virus (HPV) vaccination program on lower genital tract dysplasia and genital warts
Clark M, Jembere N, Kupets R. The impact of a universal human papilloma virus (HPV) vaccination program on lower genital tract dysplasia and genital warts. Preventive Medicine 2021, 150: 106641. PMID: 34048822, DOI: 10.1016/j.ypmed.2021.106641.Peer-Reviewed Original ResearchConceptsSchool-based human papillomavirus (HPV) vaccination programLower genital tract dysplasiaPre-invasive diseaseTreatment of HPVVaccination programGenital wartsCervical dysplasiaCytologic abnormalitiesRelative riskHuman papilloma virus vaccination programmesLow-grade cytologic abnormalitiesHuman papillomavirus vaccination programmeLower genital tractHigh-grade abnormalitiesRelative risk ratiosCervical conizationUnvaccinated womenVaccinated womenHPV vaccineColposcopy servicesUnvaccinated groupVaccinated groupRisk ratioCytology resultsAdministrative databases
2019
Successful application of prime and pull strategy for a therapeutic HSV vaccine
Bernstein DI, Cardin RD, Bravo FJ, Awasthi S, Lu P, Pullum DA, Dixon DA, Iwasaki A, Friedman HM. Successful application of prime and pull strategy for a therapeutic HSV vaccine. Npj Vaccines 2019, 4: 33. PMID: 31396405, PMCID: PMC6671986, DOI: 10.1038/s41541-019-0129-1.Peer-Reviewed Original ResearchHerpes simplex virus type 2PBS control groupRecurrent sheddingControl groupVaginal HSV-2 infectionSimplex virus type 2Herpes simplex virus vaccineRecurrent HSV diseaseTherapeutic HSV vaccinesHSV-2 infectionCombinations of vaccinesGuinea pig modelVirus type 2Imiquimod groupHSV diseaseHSV vaccineRecurrent diseaseRecurrent lesionsRecurrent HSVVaccinated groupGlycoprotein vaccineTrivalent vaccineImmune cellsVirus vaccineGenital tract
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply